MIRM FY2025 EPS Forecast Raised by Cantor Fitzgerald

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) – Stock analysts at Cantor Fitzgerald upped their FY2025 earnings per share (EPS) estimates for Mirum Pharmaceuticals in a report released on Thursday, February 27th. Cantor Fitzgerald analyst J. Schimmer now expects that the company will post earnings of ($1.40) per share for the year, up from their prior forecast of ($1.55). The consensus estimate for Mirum Pharmaceuticals’ current full-year earnings is ($1.43) per share.

Mirum Pharmaceuticals (NASDAQ:MIRM) last released its earnings results on Wednesday, February 26th. The company reported ($0.49) EPS for the quarter, missing the consensus estimate of ($0.27) by ($0.22). The business had revenue of $99.41 million during the quarter, compared to analyst estimates of $96.64 million. Mirum Pharmaceuticals had a negative net margin of 31.69% and a negative return on equity of 41.22%.

Several other research firms have also weighed in on MIRM. Citigroup lifted their price objective on Mirum Pharmaceuticals from $65.00 to $68.00 and gave the company a “buy” rating in a research note on Wednesday, November 13th. Robert W. Baird boosted their price objective on shares of Mirum Pharmaceuticals from $50.00 to $55.00 and gave the stock an “outperform” rating in a research note on Thursday, February 27th. Finally, HC Wainwright increased their price objective on shares of Mirum Pharmaceuticals from $66.00 to $72.00 and gave the stock a “buy” rating in a research report on Friday. Ten research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $58.20.

Mirum Pharmaceuticals Stock Performance

Mirum Pharmaceuticals stock opened at $45.99 on Monday. The stock has a fifty day moving average price of $47.05 and a 200 day moving average price of $43.43. Mirum Pharmaceuticals has a 52 week low of $23.14 and a 52 week high of $54.23. The company has a current ratio of 3.34, a quick ratio of 3.15 and a debt-to-equity ratio of 1.33. The firm has a market capitalization of $2.25 billion, a P/E ratio of -22.77 and a beta of 0.96.

Hedge Funds Weigh In On Mirum Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in the business. Lord Abbett & CO. LLC acquired a new position in Mirum Pharmaceuticals during the 3rd quarter worth $28,913,000. Loomis Sayles & Co. L P acquired a new position in Mirum Pharmaceuticals during the 3rd quarter valued at about $19,473,000. State Street Corp boosted its stake in Mirum Pharmaceuticals by 19.9% during the 3rd quarter. State Street Corp now owns 1,793,728 shares of the company’s stock valued at $69,955,000 after purchasing an additional 297,511 shares during the period. Erste Asset Management GmbH acquired a new position in Mirum Pharmaceuticals during the 3rd quarter valued at about $10,136,000. Finally, Raymond James Financial Inc. acquired a new position in Mirum Pharmaceuticals during the 4th quarter valued at about $10,611,000.

Insiders Place Their Bets

In other Mirum Pharmaceuticals news, SVP Jolanda Howe sold 750 shares of the company’s stock in a transaction that occurred on Tuesday, January 7th. The stock was sold at an average price of $42.82, for a total value of $32,115.00. Following the completion of the transaction, the senior vice president now owns 2,926 shares in the company, valued at $125,291.32. This represents a 20.40 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Peter Radovich sold 2,627 shares of the stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $48.22, for a total value of $126,673.94. Following the transaction, the chief operating officer now owns 26,961 shares of the company’s stock, valued at approximately $1,300,059.42. This trade represents a 8.88 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 40,915 shares of company stock worth $1,897,920 in the last 90 days. 22.87% of the stock is owned by company insiders.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.